McDermott Advises Novadiscovery on its Key Collaboration with Janssen France to Help Transform Drug R&D

Overview


International law firm McDermott Will & Emery represented Novadiscovery, a leading health tech company in its cooperation with Janssen France. Novadiscovery, which offers a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, announced yesterday that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline.

Novadiscovery aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials. Novadiscovery’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform.

Novadiscovery is headquartered in Lyon, France and has a team of around 30 scientists, engineers and clinicians who work at the interface of biology, pharmacology, mathematics and computer science.

McDermott Will & Emery worked along with Novadiscovery with a team composed of transactions / life sciences partner Anne-France Moreau and data / cybersecurity associate Lorraine Maisnier-Boché in Paris and transactions associate Jennifer Bock in Boston

About McDermott


McDermott Will & Emery is one of the world’s leading international law firms. It has more than 1,200 lawyers and 20 offices in North America and Europe. As a truly integrated platform, McDermott allows its various teams around the world to work closely and regularly together.